Dr Fayadat-Dilman is head of Protein Sciences within the Biologics Discovery organization at Merck Research Laboratories, in South San Francisco, California. She currently leads an integrated team that is responsible for expressing, purifying, engineering and characterizing reagents and therapeutic proteins for Large Molecule/ Biologics discovery research.
Her group is involved in discovering, designing and characterizing multiple biologics modalities including monoclonal antibodies, engineered proteins, bi-and multi-specific antibodies, protein scaffolds and protein/ antibody conjugates. She is responsible for the optimization and developability assessment of all Biologics Discovery projects at Merck. She Leads the initial “manufacturability” analysis on manufacturability potential of Biologics therapeutics targeting indications addressed by Merck's therapy areas. She is responsible for the interphase between Discovery and Bioprocess and CMC groups at Merck and Co.